Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $11.0 million.

  • Fulcrum Therapeutics' Total Current Liabilities fell 19.83% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 19.83%. This contributed to the annual value of $11.0 million for FY2024, which is 19.24% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Total Current Liabilities stood at $11.0 million for FY2024, which was down 19.24% from $13.7 million recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Total Current Liabilities registered a high of $26.7 million during FY2020, and its lowest value of $11.0 million during FY2024.
  • Moreover, its 3-year median value for Total Current Liabilities was $13.7 million (2023), whereas its average is $13.8 million.
  • In the last 5 years, Fulcrum Therapeutics' Total Current Liabilities surged by 120.14% in 2020 and then declined by 28.16% in 2021.
  • Fulcrum Therapeutics' Total Current Liabilities (Yearly) stood at $26.7 million in 2020, then declined by 28.16% to $19.2 million in 2021, then declined by 12.89% to $16.7 million in 2022, then dropped by 18.24% to $13.7 million in 2023, then dropped by 19.24% to $11.0 million in 2024.